Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interaction between fluconazole and rifampicin.

Literature DB >> 2224282

Interaction between fluconazole and rifampicin.

R J Coker¹, D R Tomlinson, J Parkin, J R Harris, A J Pinching.
1. St Mary's Hospital, London.

Abstract

Entities: Chemical

Mesh：

Substances：
Fluconazole
Rifampin

Year: 1990 PMID： 2224282 PMCID： PMC1663940 DOI： 10.1136/bmj.301.6755.818

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

5 in total

1. Fluconazole for cryptococcal meningitis.

Authors: R Esposito; C U Foppa; S Antinori
Journal: Ann Intern Med Date: 1989-01-15 Impact factor: 25.391

2. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors: C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal: J Infect Dis Date: 1988-01 Impact factor: 5.226

3. Treatment of infections in patients with the acquired immunodeficiency syndrome.

Authors: D Armstrong; J W Gold; J Dryjanski; E Whimbey; B Polsky; C Hawkins; A E Brown; E Bernard; T E Kiehn
Journal: Ann Intern Med Date: 1985-11 Impact factor: 25.391

4. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors: A M Sugar; C Saunders
Journal: Am J Med Date: 1988-10 Impact factor: 4.965

5. Cryptococcal meningitis in patients with AIDS.

Authors: W E Dismukes
Journal: J Infect Dis Date: 1988-04 Impact factor: 5.226

5 in total

11 in total

Review 1. Adverse drug reactions to systemic antifungals. Prevention and management.

Authors: J R Perfect; M H Lindsay; R H Drew
Journal: Drug Saf Date: 1992 Sep-Oct Impact factor: 5.606

Review 2. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors: K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal: Clin Pharmacokinet Date: 2000-02 Impact factor: 6.447

Review 3. HIV medicine: drug side effects and interactions.

Authors: C M Bates
Journal: Postgrad Med J Date: 1996-01 Impact factor: 2.401

Review 4. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Authors: R Heylen; R Miller
Journal: Genitourin Med Date: 1996-08

Review 10. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors: K L Goa; L B Barradell
Journal: Drugs Date: 1995-10 Impact factor: 9.546

Interaction between fluconazole and rifampicin.

1. Fluconazole for cryptococcal meningitis.

2. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

3. Treatment of infections in patients with the acquired immunodeficiency syndrome.

4. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

5. Cryptococcal meningitis in patients with AIDS.

Review 1. Adverse drug reactions to systemic antifungals. Prevention and management.

Review 2. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Review 3. HIV medicine: drug side effects and interactions.

Review 4. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Review 5. Clinically significant interactions with drugs used in the treatment of tuberculosis.

6. MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYA.

Review 7. Systemic antifungal agents. Drug interactions of clinical significance.

Review 8. Clinically significant drug interactions with antituberculosis agents.

9. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS.

Review 10. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.